Molecular imaging of gastroenteropancreatic neuroendocrine tumors

Area of Science:

• Oncology
• Nuclear Medicine
• Molecular Imaging

Background:

• Somatostatin-receptor scintigraphy is essential for managing neuroendocrine tumors (NETs).
• Detecting metastatic disease in NET patients relies heavily on molecular imaging.
• Advances in imaging are critical for improving NET patient outcomes.

Purpose of the Study:

• To highlight the indispensable role of somatostatin-receptor scintigraphy in NET management.
• To discuss advancements in somatostatin receptor imaging sensitivity.
• To explore other functional imaging pathways in NETs.

Main Methods:

• Somatostatin-receptor scintigraphy.
• Positron emission tomography (PET) with novel somatostatin analogues.
• Hybrid imaging techniques like PET/CT.
• Endoscopic confocal microscopy for cellular-level imaging.
• PET imaging of glucose metabolism and amine precursor uptake and decarboxylation.

Main Results:

• Somatostatin receptor imaging is a standard for suspected metastatic NETs.
• PET and new analogues significantly increase imaging sensitivity.
• Hybrid PET/CT is a preferred method in many centers.
• Research is progressing towards cellular-level somatostatin receptor imaging.
• Glucose metabolism and amine precursor uptake are other PET-accessible pathways in NETs.

Conclusions:

• Somatostatin-receptor scintigraphy is a key diagnostic tool for metastatic NETs.
• Enhanced sensitivity through PET imaging improves diagnostic accuracy.
• Integrated imaging approaches (e.g., PET/CT) are becoming standard of care.
• Future directions include cellular-level imaging and exploring diverse functional pathways.